JP2016503434A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016503434A5 JP2016503434A5 JP2015545618A JP2015545618A JP2016503434A5 JP 2016503434 A5 JP2016503434 A5 JP 2016503434A5 JP 2015545618 A JP2015545618 A JP 2015545618A JP 2015545618 A JP2015545618 A JP 2015545618A JP 2016503434 A5 JP2016503434 A5 JP 2016503434A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- fusion protein
- nucleic acid
- acid molecule
- cytokine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2012/001629 WO2014085947A1 (zh) | 2012-12-05 | 2012-12-05 | 趋化素-细胞素融合蛋白和其应用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016503434A JP2016503434A (ja) | 2016-02-04 |
| JP2016503434A5 true JP2016503434A5 (cg-RX-API-DMAC7.html) | 2017-03-30 |
| JP6174710B2 JP6174710B2 (ja) | 2017-08-02 |
Family
ID=50882722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015545618A Active JP6174710B2 (ja) | 2012-12-05 | 2012-12-05 | ケモカイン−サイトカイン融合タンパク質およびその利用 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US20150307577A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2930189B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6174710B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN104968686B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012396113B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2893981C (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014085947A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018234810B2 (en) | 2017-03-15 | 2023-05-11 | Pandion Operations, Inc. | Targeted immunotolerance |
| US10676516B2 (en) | 2017-05-24 | 2020-06-09 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| WO2020236875A1 (en) | 2019-05-20 | 2020-11-26 | Pandion Therapeutics, Inc. | Madcam targeted immunotolerance |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| TW202309270A (zh) * | 2021-04-19 | 2023-03-01 | 美商步行魚醫療公司 | 用於細胞療法的ｂ細胞擴增之方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1200479B1 (en) * | 1999-08-09 | 2006-02-01 | Lexigen Pharmaceuticals Corp. | Multiple cytokine-antibody complexes |
| CA2322687A1 (en) * | 1999-10-29 | 2001-04-29 | Regents Of The University Of California | Compositions containing c-terminal polypeptides of angiogenic chemokines and methods of use |
| AU1551801A (en) * | 1999-11-30 | 2001-06-12 | Shionogi & Co., Ltd. | Chemokine slc-il2 fused protein and gene thereof |
| EP1440090A2 (en) * | 2001-10-23 | 2004-07-28 | Centre for Translational Research in Cancer | A synthetic chimeric fusion protein with immuno-therapeutic uses |
| US20050287118A1 (en) * | 2003-11-26 | 2005-12-29 | Epitomics, Inc. | Bacterial plasmid with immunological adjuvant function and uses thereof |
| CN101445560A (zh) * | 2008-12-31 | 2009-06-03 | 河南省生物工程技术研究中心 | 一种畜禽用融合蛋白的制备方法 |
-
2012
- 2012-12-05 AU AU2012396113A patent/AU2012396113B2/en active Active
- 2012-12-05 EP EP12889511.7A patent/EP2930189B1/en active Active
- 2012-12-05 WO PCT/CN2012/001629 patent/WO2014085947A1/zh not_active Ceased
- 2012-12-05 CA CA2893981A patent/CA2893981C/en active Active
- 2012-12-05 CN CN201280077622.3A patent/CN104968686B/zh active Active
- 2012-12-05 JP JP2015545618A patent/JP6174710B2/ja active Active
- 2012-12-05 US US14/649,714 patent/US20150307577A1/en not_active Abandoned
-
2017
- 2017-07-25 US US15/658,929 patent/US10336801B2/en active Active
-
2019
- 2019-05-17 US US16/415,143 patent/US20190270788A1/en not_active Abandoned
-
2023
- 2023-03-17 US US18/122,768 patent/US20230265150A1/en active Pending